CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana, Thanyanan; Nakagawa, Kazuhiko; Chul Cho, Byoung; Cobo, Manuel; Kyung Cho, Eun; Bertolini, Alessandro; Bohnet, Sabine; Zhou, Caicun; Hyeong Lee, Ki; Nogami, Naoyuki; Okamoto, Isamu; Leighl, Natasha; Hodge, Rachel; McKeown, Astrid; P Brown, Andrew; Rukazenkov, Yuri; S Ramalingam, Suresh; Vansteenkiste, Johan

doi:10.1200/jco.2018.78.3118

Public

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Aug 28, 2018

NobleIDark:/48914/w1/20260526/5D1313DARecord on NobleID

Authors:

Thanyanan Reungwetwattana

,

Kazuhiko Nakagawa

,

Byoung Chul Cho

Abstract

Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly ...

Discussions